interleukin-12 dna
Gene therapyexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00028652)
Timeline
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- interleukin-12 dna
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02431767 | Phase 1 | Aug 1, 2015 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01440816 | Phase 2 | Nov 1, 2011 | National Cancer Institute (NCI), OncoSec Medical Incorporated, University of Washington |
| NCT00072098 | Phase 1 | Sep 1, 2003 | Icahn School of Medicine at Mount Sinai, National Cancer Institute (NCI) |
| NCT00028652 | Phase 1 | Jan 1, 2002 | National Cancer Institute (NCI), University of Wisconsin |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2002 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2015 |
| OncoSec Medical Incorporated | For profit | 1 | 1 | 1 | 2011 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2002 |
7 organizations
Page 1 / 1